comparemela.com

Latest Breaking News On - கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் - Page 18 : comparemela.com

eureKARE and DNAlytics Establish Partnership to Develop a Proprietary AI Platform

eureKARE and DNAlytics Establish Partnership to Develop a Proprietary AI Platform Unique Paris, France and Brussels, Belgium - 6 July 2021: eureKARE ( the Company ), a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announces an agreement with DNAlytics, a Belgium-based company applying data sciences to healthcare, to develop eureKARE s proprietary Artificial Intelligence (AI) platform, to support its Biotech start-up studios, eureKABIOME, to be based in France and eureKASYNBIO, to be based in Belgium. Contrary to traditional start-up incubation models, which start with novel science and then try to identify a problem to solve with it, eureKARE s approach flips this on its head. eureKARE is focused on first identifying the unmet need and then engaging the top scientists and researchers to identify an innovative solution, to eventually establish exciting ne

Investegate |MaxCyte, Inc Announcements | MaxCyte, Inc : Result of Special Meeting

Investegate |MaxCyte, Inc Announcements | MaxCyte, Inc : Result of Special Meeting
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Advicenne Receives MHRA Approval to Market Sibnayal (ADV7103) in the UK for the Treatment of dRTA

(1) Regulatory News: Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that the Medicines Healthcare products Regulatory Agency (MHRA) has today granted marketing authorisation for Sibnayal (ADV7103) in the UK, for the treatment of distal renal tubular acidosis (dRTA). With this authorization, and following the recent approval by the European Commission to market Sibnayal for the treatment of dRTA in the European Union, Advicenne is now able to bring to market in the EU and the UK the first and only label-approved drug for the treatment of dRTA in adults, adolescents and children aged one year and older. Advicenne now has the opportunity to make a significant difference to patients suffering from dRTA, classified as an orphan condition in Europe.

Advicenne Receives MHRA Approval to Market Sibnayal™

Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA July 02, 2021 01:00 ET | Source: Advicenne Advicenne A                                                                                                    Paris, France, 2 nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that the Medicines & Healthcare products Regulatory Agency (MHRA) has today granted marketing authorisation for Sibnayal™ (ADV7103) in the UK, for the treatment of distal renal tubular acidosis (dRTA). With this authorization, and following the recent approval by the European Commission to market Sibnayal™ for the treatment of dRTA in the European Union

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.